Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 4Other neoplasm 3Gastrointestinal 3CNS 3Sarcoma 2Other solid neoplasm 2Lymphoid 2Genitourinary 2Dermatologic 2Breast 2Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 728Paclitaxel 694Cyclophosphamide 647Docetaxel 559Capecitabine 485Letrozole 437Fulvestrant 398Carboplatin 397Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 272exemestane 258Epirubicin 251Radiotherapy 239pertuzumab 237palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Comparative Genomic Hybridization × Breast × Clear all
NCT00070278 2013-08-07

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
800 enrolled
Breast

Breast Neoplasms

NCT00897091 2013-05-30

S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil

SWOG Cancer Research Network

Completed
750 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡